Short answer: yes. Ocrelizumab (Ocrevus) is protected by multiple patent families, including patents on the antibody itself (composition-of-matter) and on its medical use (method-of-use) for treating multiple sclerosis (and related conditions). The exact active status depends on jurisdiction and may be different from one country to another. In many places, some use patents may still be in force, while some composition patents may have expired or are near expiry. Biologic data exclusivity can also affect market protection even after patent expiry.
What to check for in each jurisdiction:
- Composition-of-matter patents for ocrelizumab (the antibody molecule itself).
- Method-of-use patents covering treatment of multiple sclerosis (RRMS and PPMS) and possibly other autoimmune indications.
- Manufacturing, formulation, or process patents that can affect generic/biosimilar development.
- Regulatory exclusivity (e.g., biologics data exclusivity) in the country of interest, which can extend protection beyond patent terms.
How to verify current status (recommended approach):
- Search patent databases for “ocrelizumab” and the owner (Genentech/Roche) in key jurisdictions (US, Europe/EU, UK, Japan, etc.).
- US: USPTO PatFT and Patent Application Full-Text; Google Patents.
- Europe: EPO/Espacenet; Google Patents.
- WIPO: PATENTSCOPE.
- Use terms like: “ocrelizumab”, “anti-CD20”, “MS”, “multiple sclerosis”, “use in MS”, “method of use”, and look at patent families to see expiration dates and legal status (Active/Expired/Expired due to fees, etc.).
- Check for patent term extensions or regulatory data exclusivity in the region, which can keep protection in force beyond patent expiry.
- Look for any ongoing or settled litigation or licensing that might influence enforceability.
If you want, I can look up current active patents for ocrelizumab in specific jurisdictions (e.g., US and EU) and summarize which claims are still in force, their expiration dates, and any relevant exclusivity. Tell me which countries you care about, and I’ll pull together a concise status report.